Dynavax Technologies Corporation (NASDAQ: DVAX) announced that Phase 3 trial comparing HEPLISAV to a currently marketed HBV vaccine, Engerix-B, demonstrated ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE